*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*                                                                     *x*
*x*            Copyright (C) 1990 University of Pennsylvania            *x*
*x*                                                                     *x*
*x*    The data in this file are part of a preliminary version of the   *x*
*x*    Penn Treebank Corpus.  Any research using this corpus or based   *x*
*x*    on it should acknowledge that fact, as well as the preliminary   *x*
*x*    nature of the corpus.                                            *x*
*x*                                                                     *x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*
*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*x*



======================================

[ Immunex/NNP Corp./NNP ]
announced/VBD 
[ a/DT series/NN ]
of/IN 
[ agreements/NNS ]
under/IN 
[ which/WDT ]

[ the/DT biotechnology/NN company/NN ]
will/MD reacquire/VB 
[ the/DT right/NN ]
to/TO 
[ manufacture/VB ]
and/CC 
[ market/VB promising/JJ biological/JJ agents/NNS ]
for/IN 
[ treatment/NN ]
of/IN 
[ cancer/NN ]
and/CC 
[ immune/JJ dysfunction/NN ]
./. 

======================================

Among/IN 
[ product/NN rights/NNS ]
reacquired/VBN was/VBD 
[ granulocyte-macrophage/NN colony/NN stimulating/VBG factor/NN ]
,/, or/CC 
[ GM-CSF/NNP ]
,/, 
[ which/WDT ]
promotes/VBZ 
[ growth/NN ]
of/IN 
[ infection-fighting/JJ white/JJ blood/NN cells/NNS ]
./. 

In/IN 
[ a/DT recent/JJ study/NN ]
,/, 
[ GM-CSF/NNP ]
reduced/VBD 
[ deaths/NNS ]
following/VBG 
[ bone-marrow/NN transplants/NNS ]
in/IN 
[ cancer/NN patients/NNS ]
./. 

[ Immunex/NNP plans/NNS ]
to/TO file/VB 
[ an/DT application/NN ]
for/IN 
[ Food/NNP ]
and/CC 
[ Drug/NNP Administration/NNP approval/NN ]
of/IN 
[ GM-CSF/NNP ]
for/IN 
[ this/DT use/NN ]
late/RB 
[ this/DT year/NN ]
./. 

======================================

[ Immunex/NNP ]
,/, 
[ which/WDT ]
in/IN 
[ the/DT early/JJ 1980s/CD ]
licensed/VBD away/RB 
[ the/DT right/NN ]
to/TO make/VB and/CC sell/VB 
[ products/NNS ]

[ it/PRP ]
had/VBD developed/VBN ,/, now/RB has/VBZ shifted/VBN 
[ gears/NNS ]
and/CC is/VBZ reclaiming/VBG 
[ rights/NNS ]
to/TO 
[ such/JJ products/NNS ]
as/IN 
[ part/NN ]
of/IN 
[ its/PRP$ strategy/NN ]
of/IN becoming/VBG ``/`` 
[ a/DT ]
fully/RB integrated/VBN 
[ biopharmaceutical/JJ company/NN ]
,/, ''/'' said/VBD 
[ Stephen/NNP A./NNP Duzan/NNP ]
,/, 
[ chairman/NN ]
,/, 
[ president/NN ]
and/CC 
[ chief/NN executive/NN officer/NN ]
./. 

======================================

Under/IN 
[ the/DT first/JJ ]
of/IN 
[ several/JJ related/VBN agreements/NNS ]
,/, 
[ Immunex/NNP ]
agreed/VBD with/IN 
[ the/DT Sterling/NNP Drug/NNP Inc./NNP unit/NN ]
of/IN 
[ Eastman/NNP Kodak/NNP Co./NNP ]
to/TO 
[ restructure/VB ]

[ a/DT joint/JJ venture/NN ]
./. 

Under/IN 
[ terms/NNS ]
of/IN 
[ the/DT pact/NN Immunex/NNP ]
paid/VBD nearly/RB 
[ $/$ 5/CD million/CD ]
for/IN 
[ the/DT rights/NNS ]
to/TO 
[ market/VB ]
and/CC 
[ manufacture/VB interleukin-1/NN receptor/NN ]
,/, 
[ interleukin-4/NN receptor/NN ]
,/, and/CC 
[ B-cell/NN differentiation/NN factor/NN ]
./. 

[ Immunex/NNP ]
said/VBD 
[ the/DT payment/NN ]
will/MD be/VB made/VBN out/IN of/IN 
[ cash/NN reserves/NNS ]
during/IN 
[ the/DT third/JJ quarter/NN ]
./. 

======================================

[ The/DT experimental/JJ agents/NNS ]
generally/RB are/VBP thought/VBN to/TO have/VB 
[ potential/NN ]
for/IN controlling/VBG 
[ various/JJ aspects/NNS ]
of/IN 
[ the/DT human/JJ immune/NN response/NN ]
,/, 
[ Immunex/NNP ]
said/VBD ./. 

[ Sterling/NNP ]
,/, for/IN 
[ its/PRP$ part/NN ]
,/, received/VBD 
[ rights/NNS ]
to/TO 
[ certain/JJ so-called/JJ rational/JJ drug/NN design/NN projects/NNS ]
and/CC 
[ other/JJ product/NN development/NN projects/NNS ]
./. 

======================================

In/IN 
[ a/DT related/VBN move/NN ]
,/, 
[ Immunex/NNP ]
said/VBD 
[ it/PRP ]
acquired/VBD from/IN 
[ Behringwerke/NNP AG/NNP ]
of/IN 
[ West/NNP Germany/NNP ]

[ the/DT manufacturing/NN ]
and/CC 
[ co-marketing/JJ rights/NNS ]
to/TO 
[ certain/JJ colony/NN ]
stimulating/VBG 
[ factors/NNS ]
,/, including/VBG 
[ GM-CSF/NNP ]
,/, and/CC 
[ interleukin-3/NN ]
./. 

In/IN 
[ return/NN ]
,/, 
[ Behringwerke/NNP ]
received/VBD 
[ rights/NNS ]
to/TO 
[ certain/JJ Immunex/NNP receptor/NN products/NNS ]
outside/JJ of/IN 
[ North/NNP America/NNP ]
./. 

======================================

[ Behringwerke/NNP ]
also/RB received/VBD 
[ an/DT option/NN ]
to/TO 
[ manufacture/VB ]
and/CC 
[ market/VB ]
in/IN 
[ Japan/NNP ]

[ the/DT receptor/NN products/NNS ]
./. 

If/IN exercised/VBN ,/, 
[ these/DT rights/NNS ]
would/MD require/VB 
[ Behringwerke/NNP ]
to/TO pay/VB 
[ a/DT license/NN fee/NN ]
,/, 
[ which/WDT Immunex/NNP ]
said/VBD would/MD offset/VB 
[ its/PRP$ payment/NN ]
to/TO 
[ Kodak/NNP 's/POS Sterling/NNP unit/NN ]
./. 
